Amylin Pharmaceuticals to Present at First Annual Research & Development Breakfast
Posted on: Friday, 20 October 2006, 18:01 CDT
SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. will be presenting at its first annual Research & Development Breakfast on Tuesday, October 24, 2006 at 7:30 a.m. ET at the Grand Hyatt Hotel in New York.
"Amylin's approach to discovering first-in-class medicines is yielding exciting results. At our first-ever Research and Development event, we will share our progress and plans," said Ginger L. Graham, Chief Executive Officer of Amylin Pharmaceuticals.
The presentation agenda for the R&D Breakfast includes: * Introduction/Corporate Overview Ginger L. Graham CEO, Amylin Pharmaceuticals * Clinical Development Orville Kolterman, MD Senior Vice President of Clinical and Regulatory Affairs, Amylin Pharmaceuticals * Early Development Alain Baron, MD Senior Vice President of Research, Amylin Pharmaceuticals * Discovery Research Michael Hanley, PhD Vice President of Discovery Research, Amylin Pharmaceuticals * Closing Remarks Daniel M. Bradbury President and Chief Operating Officer A question and answer session will follow the presentations.
The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com/. To access the live webcasts, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes, obesity and cardiovascular disease. Amylin is located in San Diego, California with over 1250 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com/.
Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of AmylinPharmaceuticals, Inc., +1-858-552-2200, ext. 7272
Web site: http://www.amylin.com/
Source: PRNewswire-FirstCall
Related Articles
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
- Burnham Announces Assay Development and License Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
- Ortho Biotech Oncology Research & Development Unites Johnson & Johnson Biopharmaceutical Oncology R&D Assets
- Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
- Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial With VELCADE(R) (Bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma
- Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completes Submission of Tipifarnib NDA to FDA Continuous Marketing Application Pilot-1 Program
- Amylin Pharmaceuticals Provides Update On Clinical Development Programs
 |
 |
User Comments (0)
RSS Feeds